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Abstract
Objective: Pneumocystis jirovecii pneumonia (PCP), the commonest opportunistic infection in HIV-infected patients in the
developed world, is less commonly described in tropical and low and middle income countries (LMIC). We sought to
investigate predictors of PCP in these settings.
Design: Systematic review and meta-regression.
Methods: Meta-regression of predictors of PCP diagnosis (33 studies). Qualitative and quantitative assessment of recorded
CD4 counts, receipt of prophylaxis and antiretrovirals, sensitivity and specificity of clinical signs and symptoms for PCP, co-
infection with other pathogens, and case fatality (117 studies).
Results: The most significant predictor of PCP was per capita Gross Domestic Product, which showed strong linear
association with odds of PCP diagnosis (p,0.0001). This was not explained by study design or diagnostic quality.
Geographical area, population age, study setting and year of study also contributed to risk of PCP. Co-infection was
common (444 episodes/1425 PCP cases), frequently with virulent organisms. The predictive value of symptoms, signs or
simple tests in LMIC settings for diagnosis of PCP was poor. Case fatality was .30%; treatment was largely appropriate.
Prophylaxis appeared to reduce the risk for development of PCP, however 24% of children with PCP were receiving
prophylaxis. CD4 counts at presentation with PCP were usually ,2006103/ml.
Conclusions: There is a positive relationship between GDP and risk of PCP diagnosis. Although failure to diagnose infection
in poorer countries may contribute to this, we also hypothesise that poverty exposes at-risk patients to a wide range of
infections and that the relatively non-pathogenic P. jirovecii is therefore under-represented. As LMIC develop economically
they eliminate the conditions underlying transmission of virulent infection: P. jirovecii, ubiquitous in all settings, then
becomes a greater relative threat.
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Introduction
Pneumocystis jirovecii pneumonia (PCP) is one of the commonest
opportunistic infection in Human Immunodeficiency Virus (HIV)-
infected patients in the developed world (historically the leading
AIDS-indicator disease in both the United States and Europe) [1],
but has always been regarded as rare in low and middle income
countries (LMIC) predominantly of tropical latitude [2,3].
However, the organism is ubiquitous and seroprevalence data
indicates worldwide exposure [4–7]. This suggests that epidemi-
ological differences are not explained by geography, nor are they
easily attributable to genetic differences in the organism or the host
[8,9]. Factors influencing prevalence in these settings have not
been systematically evaluated.
Our primary objective was to establish major determinants of
PCP in HIV-infected individuals in tropical and LMIC. The ‘gold’
diagnostic standard of cytological examination of respiratory
samples may be less available in LMIC, affecting reported
prevalence. Gross domestic product (GDP), a measure of
population income level, influences prevalence of HIV and
opportunistic infections including tuberculosis [10,11], and an
association with PCP may thus be discovered. Relationships with
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time, geographical area or study setting may reflect genuine
epidemiology [12], but might also reflect varying awareness of the
condition among clinicians [13].
Additionally, assessment of the accuracy of symptoms, signs, or
laboratory tests in LMIC for diagnosis of PCP, rates of co-infection
that may confound diagnosis [14], PCP case fatality, CD4 count at
presentation, treatment strategies, and efficacy of prophylaxis or
antiretroviral therapy (ART) in reducing risk of PCP was
undertaken.
Methods
Search Strategy and Study Selection
Table 1 details the search strategy. Summaries of AIDS-defining
illnesses (ADI) or hospitalisations in the HIV-infected population
were included for primary analysis, since these were considered
most representative of overall disease burden and their broad entry
criteria carried minimal risk of bias. Presumptive diagnoses were
included, consistent with practice in many centres [1], although
quality of diagnosis was also assessed. All HIV-infected partici-
pants in the studies were included. DML extracted and RFM
verified the data.
Quality Assessment
A modified Newcastle Ottawa Scale (NOS) was used to assess
selection and comparability of patients (Table 2). Since most
studies in the primary analysis did not control for specific features,
comparability was assessed on the basis of identical recruitment of
PCP and non-PCP cases. Quality of outcome ascertainment was
assessed by a quantitative diagnostic scoring system (Table 2).
Clinical diagnosis only scored ‘1’; diagnosis based solely on
spontaneously expectorated sputum scored ‘2’. Values between 3
and 5 indicate that appropriate advanced diagnostics were
available and used for some, but not all, patients. A score of ‘6’
was awarded if all patients were diagnosed with high accuracy.
Polymerase Chain Reaction (PCR) methods for diagnosing PCP
were only being validated towards the end of the time range of
Table 1. Search strategy.
Databases searched PubMed database (provided by the US National Library of Medicine)
Cochrane Library
African Journals Online
First/Last performed March 2006/January 2011
Search terms pneumocystis, carinii, jiroveci, jirovecii, PCP, PJP
Cross-referenced with: Africa, Asia, Middle East, India, South America, Central America, Latin America, developing world, tropics
Study designs included Prospective or cross-sectional clinical studies
Retrospective reviews of medical records/databases
Cohort studies
Autopsy/mortality studies
Data extracted Year(s) studied
Year published
Study methodology
Country
Specific study setting and population
Method(s) of diagnosis for PCP
Total number of patients included
Total number of patients with HIV
Number of patients with PCP (sub-divided according to HIV status)
Total number of patients with tuberculosis (TB) (sub-divided according to HIV status)
Specific clinical findings in patients with PCP
Prior receipt of antiretrovirals amongst patients with and without PCP
Prior receipt of PCP prophylaxis amongst patients with and without PCP
CD4 count in patients with PCP
Co-infection in patients with PCP
Mortality amongst patients with PCP
Treatment strategy of patients with PCP
Exclusion criteria Published before 1985
Non-English language
Study setting outside pre-specified geographical areas (Central or South America, East or South-East Asia, Indian sub-
continent, Middle East, Africa)
Definite subset of data published elsewhere (possible overlap of patients is indicated in relevant tables)
Unable to extract data
PCP/PJP = Pneumocystis jirovecii pneumonia; HIV =Human Immunodeficiency Virus; CD4=Cluster of Differentiation 4.
doi:10.1371/journal.pone.0069969.t001
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Table 2. Quality scores for studies included in primary analysis.
Study Selection score (1 point per item)
Comparability score (1
point per item) Diagnostic score
- Inclusion/Exclusion criteria clearly
stated?
- PCP and non-PCP cases
recruited identically?
Samples/diagnostic tests Score
- Cases clearly representative (eg
consecutive)?
- Patients on/not on
prophylaxis recruited
identically? (Where applicable)
Clinical diagnosis (empirically
diagnosed)
1
- Numbers/reasons for non-inclusion
clearly stated?
Clinical diagnosis (empirically
diagnosed) or histochemical/IF
staining of spontaneously
expectorated sputum/NPA
2
- Method for ascertaining whether PCP
prophylaxis was used clearly stated and
acceptable? (Where applicable)
Clinical diagnosis (empirically
diagnosed) or histochemical/IF
staining of induced sputum
3
Clinical diagnosis (empirically
diagnosed) or histochemical
staining of BAL fluid
4
Clinical diagnosis (empirically
diagnosed) or histochemical/IF
staining of induced sputum or
histochemical staining of BAL
fluid or lung tissue (TBB/OLB)
5
Histochemical staining/IF of
induced sputum or histochemical
staining of BAL fluid or lung
tissue (TBB/OLB) – all patients
6
Moreira-Junior [52] 3 1 5
Udwadia [53] 2 1 6
Sharma [54] 3 1 5
Bellamy [55] 3 1 NR
Nissapatorn 2003 [56] 1 1 1
Singh [57] 0 1 2
Kim [58] 0 1 NR
Senya [20] 2 1 1
Inverarity [59] 2 1 1
Kumarasamy [60] 1 1 NR
Louie [61] 2 1 6
Anekthananon [37] 2 1 NR
Fang [62] 3 1 5
Oh [63] 2 1 5
Tansuphasawadikul [64] 3 1 1
Yoong [41] 1 1 NR
George [65] 2 1 1
Siegman-Igra [44] 3 1 NR
Nissapatorn 2004 [66] 1 1 1
Lian [22] 3 1 NR
Santos [67] 2 1 NR
al-Haddad [45] 2 1 NR
Tan [68] 3 1 NR
Swasdisevi [69] 0 1 1
Vithayasi [70] 0 1 NR
Kong [71] 2 1 5
Chariyalertsak [25] 1 1 1
Wong [72] 2 1 NR
Shah [73] 2 1 NR
Rajasekaran [74] 2 1 1
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these studies. Correspondingly, accuracy was not established and
no studies used PCR alone without either immunofluorescence or
cytology for diagnosis: for these reasons, PCR is not included in
the scoring system.
Bias and Confounding
Within-study bias mostly derived from entry criteria specifying
pre-existing diseases or clinical characteristics. Studies with biased
entry criteria were excluded from pooled analysis. Increased
clinical diagnosis of PCP resulting from greater awareness among
clinicians may have created bias, but we could not formally assess
this. We planned to control for time and geographical area in an
attempt to eliminate or identify this bias. Population characteristics
may vary depending on the type of research institution and so we
also aimed to control for this variable.
Analysis and Statistics
Primary analysis was performed using logistic regression. The
dependent variable was diagnosis of PCP (present/absent).
Categorical predictor variables were study population (adult,
paediatric, combined, unspecified); geographical area (Africa,
Middle East, Indian sub-continent, East/South-East Asia, Cen-
tral/South America) and study setting (rural/primary care,
hospital, tertiary/specialist/University hospital, nationwide).
Quality assessments (selection score and diagnostic score) were
treated as categorical predictors. Due to low numbers within some
diagnostic score groups, values were combined into categories of
‘Low quality’ (score 1 or 2), ‘High quality’ (score 5 or 6) or ‘Not
Recorded’. Per capita GDP in ‘constant US dollars’ (after
controlling for inflation) was obtained from the World Bank’s
world development indicators for the median year of the study
[15]. Median year of study and GDP were treated as continuous
covariates. Year was centred to its mean; GDP showed a skewed
distribution and was centred to its median. When the effects of
GDP and year were seen to be non-linear a quadratic term was
added. Relative importance of model components was assessed via
Chi-square improvement (based on -26Log Likelihood) with
iterative addition of predictors.
Case fatality was assessed using logistic regression with death/
survival as the dependent variable and the same predictors (as
above). Odds Ratios for the effect of prophylaxis were calculated
using Mantel-Haenszel methodology. A forest plot was used to
assess heterogeneity in prevalence in studies selected for primary
analysis; heterogeneity in case fatality and prophylaxis data was
assessed via I2 analysis. Statistics were performed using SPSS
version 18.0; meta-analysis functions were performed with Review
Manager Version 5.1 (Cochrane Collaboration 2011, Copenha-
gen).
Results
Of 1708 citations identified, 134 full-text papers were reviewed.
Ten contained no identifiable data and seven were subsets of data
published elsewhere (see Figure 1 for a PRISMA [16] flowchart;
see Checklist S1 for the PRISMA checklist). Table 3 summarises
the remaining 117 studies. Papers reviewed but not specifically
cited in the text are included as Supplementary References
(References S1). Eleven studies were from high income countries
and 106 were from LMIC. Seventy-eight studies (67%) were
performed in University/tertiary/specialist centres, 25 (21%) were
performed in other (or undefined) hospital settings, five (4%) in
rural healthcare facilities, seven (6%) were nationwide/regional
studies and two (2%) reported occupational health services at
mines.
Forty-six studies declared their treatment for PCP (Figure 2): 39
used co-trimoxazole, of which 19 mentioned concomitant use of
steroids; four used pentamidine, two used clindamycin plus
Figure 1. Results of literature search.
doi:10.1371/journal.pone.0069969.g001
Table 2. Cont.
Study Selection score (1 point per item)
Comparability score (1
point per item) Diagnostic score
Solomon [75] 2 1 NR
Soares [76] 3 1 1
Bedri [77] 3 1 1
PCP – Pneumocystis jirovecii pneumonia; IF = Immunofluorescence; NPA =nasopharyngeal aspirate; BAL = bronchoalveolar lavage; TBB = trans-bronchial biopsy;
OLB= open lung biopsy; NR =Not Recorded.
doi:10.1371/journal.pone.0069969.t002
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primaquine or pyrimethamine and one used dapsone. There were
few data on the effect of ART on PCP prevalence. Several papers
documented that no patients were taking ART at the time of
presentation [17–21]. Lian et al [22] demonstrated a decline in
PCP incidence from 21/128 (16.4%) prior to availability of ART
to 1/128 (0.78%) subsequently; Kouakoussui et al [23] reported
two cases of PCP in their cohort before availability of ART and
none after. However, Brazilian mortality data [24], reported that
81 of 403 (est.) deceased PCP patients had received ART.
PCP Prevalence is more Dependent on per capita Gross
Domestic Product than any Other Factor
Thirty-five studies detailed ADI or reasons for hospitalisation
within an HIV-infected population, but two pre-specified ‘fever of
unknown origin’ and were excluded from primary analysis due to
recruitment bias. The remaining 33 studies represented 114,389
people and 21,853 PCP diagnoses. However, one Thai surveil-
lance study [25] accounted for 101,945 people and 20,145
diagnoses. Results are reported including this study, since
removing it from analysis did not significantly alter findings. The
overall median year of study was 1996 and median GDP was
$2141 per capita. The prevalence of PCP as an ADI/reason for
Table 3. Classification of reviewed studies.
Africa
Indian sub-
continent
Central and
South America
East and South-
East Asia Middle East
Respiratory studies Adult 18 Adult 2 Adult 1 Adult 7
Paed 11 Paed 1 Paed 1
Unspec 1
Autopsy studies Adult 3 Adult 1 Adult 3 Paed 1
Paed 6 Paed 1 Comb 2
Other mortality data Adult 4 Adult 1 Paed 1
AIDS defining illnesses or Paed 1 Adult 6 Adult 3 Adult 17 Adult 2
reasons for Paed 2 Comb 1 Comb 2
hospitalisation in HIV infected
population
Comb 1
HIV Cohort studies Adult 1 Paed 6 Adult 1 Adult 3 Adult 1
Paed 1 Comb 1 Paed 1 Comb 2
Non-HIV immunocompromised
populations1
Adult 3
1Not included in analysis.
AIDS =Acquired Immunodeficiency Syndrome; HIV =Human Immunodeficiency Virus; Paed = paediatric; Comb= combined adult and paediatric; unspec = unspecified
age group.
doi:10.1371/journal.pone.0069969.t003
Figure 2. Treatment strategies for PCP in reviewed studies. Total strategies for this analysis = 46.
doi:10.1371/journal.pone.0069969.g002
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hospitalisation ranged from 1.67% to 60.0%. Initial assessment of
heterogeneity (Figure 3) suggested that summary measures were
inappropriate and we proceeded to meta-regression.
There was a positive linear relationship between median year of
study and odds of PCP (adjusted odds ratio (aOR) per year = 1.05,
95% CI 1.03–1.07, p,0.001). Geographical area was a significant
predictor, with higher odds for a diagnosis of PCP in Central/
South America (aOR = 1.72, 95% CI 1.35–2.19, p,0.001) and
the Middle East (aOR = 2.53, 95% CI 1.46–4.39, p = 0.001) versus
East/South-East Asia. However, there were only two studies from
the Middle East (total n = 63), and so we interpreted this result
cautiously. Adult or combined-age studies yielded lower odds for
PCP than paediatric studies (for adult studies aOR = 0.67, 95% CI
0.52–0.86, p = 0.002; for combined studies aOR = 0.70, 95% CI
0.56–0.87, p = 0.001). Nationwide surveillance demonstrated
higher odds than hospital studies (secondary or tertiary care),
with the lowest odds in rural/primary care centres, although only
one rural study (n = 225) was included (versus nationwide studies:
aOR for tertiary/University hospitals = 0.46, 95% CI 0.35–0.60,
p,0.001; aOR for other hospitals = 0.47, 95% CI 0.33–0.68,
p,0.001; aOR for rural/primary care studies = 0.28, 95% CI
0.16–0.50, p,0.001).
GDP was a highly significant linear predictor of a diagnosis of
PCP (p,0.0001). An increase of $20,000 (the approximate range
of GDPs included) increases the odds for a diagnosis of PCP 10.54-
fold (95% CI 8.41–13.20). Chi-square improvement analysis
revealed GDP to be the most important predictor of a diagnosis
of PCP (order of importance: GDP.population age.geographi-
cal area.study setting.median year). Results from logistic
regression are summarised in Table 4. Figure 4A provides a
graphical representation of prevalence data compared with GDP
for adult studies; tuberculosis (TB) prevalence in the same studies is
depicted in Figure 4B and shows a decline with increasing GDP, as
previously described [11]. In these data, the correlation between
PCP prevalence and GDP was 0.78 (p,0.001) unweighted, or
0.94 (p,0.001) weighted by study size; the correlation between TB
prevalence and GDP was -0.61 (p = 0.001) unweighted, or -0.57
(p,0.001) weighted by study size.
Since Africa was under-represented in these data we also
analysed the most common African study type, adult clinical
studies of sub-acute respiratory illness (note there is some
heterogeneity in entry criteria). There were 2109 HIV-infected
patients and 277 PCP cases from 18 studies. There was a linear
relationship between GDP and odds of PCP (p = 0.021); an
increase of $20,000 increased the odds for PCP 37.2-fold (95% CI
1.74–794.2). There were lower odds for PCP in rural settings than
hospitals (aOR = 0.28, 95% CI 0.08–0.96, p = 0.042) and a
quadratic relationship with time showing a fall in odds followed
by a rise over the included years (Table 5).
Quality Assessments do not Explain the Associations
Observed
Applying our modified NOS to the primary analysis, we
concluded that patient comparability was acceptable since all
studies recruited PCP and non-PCP cases identically (Table 2).
Each study was also assessed according to the first three Selection
parameters and awarded a score from 0 to 3. Selection score was
not a significant predictor of PCP diagnosis in logistic regression,
and a strong relationship with GDP persisted when analysis was
restricted to studies which met two or more criteria (24 studies).
Diagnostic score was a significant predictor of PCP diagnosis in
logistic regression (p,0.001). Lowest odds were seen in the ‘Low
quality’ group, but both ‘Low quality’ and ‘High quality’ studies
showed lower odds than the ‘Not Recorded’ group. However, after
including diagnostic score as a predictor the only differences in
other results were that the relationship with time became
quadratic, plateauing between 2000–2001 (p = 0.002), and that
lower odds of PCP were seen in Indian studies compared with
East/South-East Asia (Table 4). GDP remained the strongest
predictor using Chi-square improvement analysis; an increase in
GDP of $1,000 in this model increased the odds for diagnosis of
PCP 1.10-fold (95% CI 1.09–1.12). Restricting analysis to studies
with high diagnostic quality (7 studies with score 5 or 6) revealed
similar results to the overall analysis: an increase in GDP of $1,000
increased the odds for diagnosis of PCP 1.14-fold (95% CI 1.09–
1.20, p,0.001). The African clinical studies generally diagnosed
PCP with a high degree of certainty, with a Diagnostic Score of ‘6’
for 15 studies, ‘5’ for two studies and ‘2’ for only one study. No
correlations existed between quality scores and either GDP or
median year, including quality scores as fixed factors and
controlling for other predictors in a linear regression model. In
particular, there was no significant relationship between GDP and
diagnostic score.
Diagnostic Value of Clinical Symptoms, Signs or Simple
Tests are Generally Poor for PCP in Low Income Settings
We evaluated individual symptoms, signs, diagnostic tests and
aspects of patient history for their ability to predict the presence or
Figure 3. Prevalence of PCP in studies included for primary
analysis, indicating heterogeneity of data set. Confidence
intervals for point prevalences were determined by adjusted Wald
method.
doi:10.1371/journal.pone.0069969.g003
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absence of a PCP diagnosis. Seven adult studies [26–32] (total 701
patients, 177 with PCP) and five paediatric studies [21,33–36]
(total 550 patients, 192 with PCP) were included; parameters
detailed in three or more papers are displayed in Figure 5. Pooled
estimates are not provided due to high heterogeneity. Indicators of
PCP with high sensitivity and negative predictive value, for
example cough or dyspnoea, generally had poor specificity and
positive predictive value. Certain indicators pointing against a
diagnosis of PCP, for example haemoptysis, demonstrated high
specificity for a subset without PCP, but poor overall sensitivity for
‘PCP-negatives’.
Co-infection is Common with PCP in Tropical and LMIC
Settings
Table 6 demonstrates documented co-infections among 1,425
PCP patients, derived from 49 studies. These represent infectious
rather than patient episodes and frequently a single patient had
multiple co-existing infections. Studies whose entry criteria
depended on a prior infectious diagnosis other than HIV (eg
tuberculosis) were excluded from this analysis. There was a bias
towards respiratory pathogens, with many studies basing all
analysis on sputum/bronchial washings or including only patients
with respiratory symptoms. M.tuberculosis accounted for at least 103
of 444 episodes (23.2%). Cytomegalovirus (CMV) was found in
104 episodes (23.4%). Bacterial infection (generally with virulent
organisms, where specified) was identified in 116 episodes (26.1%).
Case Fatality from PCP in Tropical and LMIC Settings is
High, is not Improving with Time, but Negatively
Correlates with GDP
Table 7 details case fatality rates among people with a PCP
diagnosis in the included studies. Because entry criteria differed
between geographical areas, it was not considered valid to
compare case fatality rates between regions. There was consider-
able heterogeneity in these data (I2.90% for all datasets except
adult mortality in Central/South America), making us interpret
pooled estimates cautiously. Nevertheless, as an indicative figure
the overall case fatality from all studies in LMIC was 226/733
(30.9%, 95% CI 27.6%–34.3%). Limiting analysis to studies with
diagnostic score 5 or 6 (22 studies) revealed a pooled case fatality
estimate of 31.4%, and limiting to confirmed diagnoses (Score 6;
16 studies) revealed a pooled estimate of 28.5%. There was no
significant time trend in case fatality rates, as assessed by logistic
regression (p = 0.894). However, there was a significant negative
Figure 4. Relationship between prevalence of diagnoses and GDP. A. Relationship between Pneumocystis jirovecii pneumonia (PCP)
prevalence (%) and per capita Gross Domestic Product (constant US$) in adult AIDS-defining illness studies or reasons for hospitalisation in an HIV
infected population; size of marker indicates size of study; a regression line is added for clarity. Note the logarithmic x-axis. B. Relationship between
tuberculosis (TB) prevalence (%) and per capita Gross Domestic Product (constant US$) for the same studies.
doi:10.1371/journal.pone.0069969.g004
Table 4. Results of primary analysis of predictors of PCP via logistic regression.
Excluding diagnostic score Including diagnostic score
Predictor Exp(B) 95% CI p-value Exp(B) 95% CI p-value
Median year (per
year)
1.05 1.03–1.07 ,0.001 N/A
Median year
(quadratic)
N/A …1 0.002
GDP (per $1000) 1.12 1.11–1.14 ,0.0001 1.10 1.09–1.12 ,0.0001
Study Population Adult 0.67 0.52–0.86 0.002 0.35 0.24–0.52 ,0.001
Combined 0.70 0.56–0.87 0.001 0.36 0.25–0.50 ,0.001
Paediatric 1 1
Geographical area Africa 1.34 0.64–2.81 0.443 0.70 0.32–1.57 0.389
India 0.95 0.77–1.17 0.632 0.65 0.50–0.86 0.002
Middle East 2.53 1.46–4.39 0.001 3.47 1.84–6.55 ,0.001
Central/South America 1.72 1.35–2.19 ,0.001 2.29 1.70–3.09 ,0.001
East/South-East Asia 1 1
Study setting Rural/primary care 0.28 0.16–0.50 ,0.001 0.27 0.15–0.49 ,0.001
Hospital
(secondary level)
0.47 0.33–0.68 ,0.001 0.45 0.31–0.66 ,0.001
Hospital (tertiary
or University)
0.46 0.35–0.60 ,0.001 0.40 0.30–0.54 ,0.001
Nationwide
surveillance
1 1
Diagnostic score Low quality N/A 0.57 0.46–0.70 ,0.001
High quality N/A 0.76 0.62–0.93 0.007
Not Recorded N/A 1
1Odds defined by Exp(0.068–0.007–260.0076[Mean of all study median years – Median year of specific study]).
CI = confidence interval; GDP =per capita Gross Domestic Product (constant US$). N/A =Not Applicable.
doi:10.1371/journal.pone.0069969.t004
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relationship with GDP, which persisted after controlling for
geographical area (the only other significant predictor in
univariate analysis, likely confounded by study design). The crude
OR for case fatality per $1000 increase in GDP was 0.96 (95% CI
0.92–1.00, p = 0.047), and adjusted OR = 0.86 (95% CI 0.79–
0.94, p = 0.001).
PCP Prophylaxis Appears Effective
Three adult studies [28,37,38] (total 445 patients) and four
paediatric studies [21,33,34,39] (total 524 patients) detailed
prophylaxis use amongst patients with PCP in resource-poor
settings. Table 8 details odds ratios and quality assessments for
these studies. Data is not pooled due to differences in study design
and populations. All studies indicated reduced odds for PCP
amongst patients taking prophylaxis, although only three signif-
icantly so.
CD4 Count at Presentation with PCP is Generally
,2006103/ml, but is Higher in LMIC than in High Income
Countries
Table 9 details available data on CD4 count at presentation
with PCP. Most studies report a mean or median CD4 count
,2006103/ml in adults. Certain populations were documented to
have higher CD4 counts: Malaysian intravenous drug users [40]
(mean = 5766103/ml) and [41] (range 310-16816103/ml), and
Filipino commercial sex workers [42] (mean = 3646103/ml).
However, we are unable to confirm diagnosis in these studies:
two report the use of ‘sputum’, for either ‘staining’ [40] or
immunofluorescence [42], but not how it was obtained. Median
CD4 counts at presentation with PCP in adults in LMIC were
higher than in high income countries (p = 0.028, Mann-Whitney
U-test, excluding [41] as a clear outlier).
Discussion
The most significant finding from this analysis is that the
odds of a PCP diagnosis as an ADI or reason for hospitalisation
in the HIV-infected population are strongly and positively
correlated with per capita GDP. Although failure to make the
diagnosis in resource-poor countries may contribute to this
relationship (discussed below), we hypothesise that the relative
scarcity of PCP in LMIC is primarily a result of poverty. In
conditions of poverty, HIV-infected individuals are exposed to
many infectious agents and non-infectious health challenges
resulting in hospitalisation: these risks are compounded by weak
health systems with poor preventative healthcare. In situations
of high ‘pathogen competition’, relatively non-pathogenic
organisms such as Pneumocystis will be under-represented. As
countries develop economically they reduce health risks and
improve the conditions underlying transmission of contagious
infection: as reflected in the decreasing prevalence of tubercu-
losis with increasing GDP (Figure 4B). Similarly, there is a
highly significant negative correlation between per capita GDP
[15] and WHO age-standardized death rates (available at
http://www.who.int/healthinfo/global_burden_disease/estimates
_country/en/index.html) from meningitis or lower respiratory
tract infections (Pearson correlation coefficient for meningitis -0.39,
p,0.0001, n = 166 countries; Pearson correlation coefficient for
respiratory infection -0.43, p,0.0001, n = 168 countries), suggest-
ing a higher burden of severe illness with virulent pathogens in
poorer countries. Pneumocystis jirovecii, ubiquitous in all settings, thus
becomes a greater relative threat with economic advancement. The
implicit conclusion is that HIV-infected people in wealthy countries
are ‘protected’ from early presentation, since their CD4 count can
drop into the range of risk for PCP before they develop illness.
As mentioned above, another explanation for the association
between risk of PCP and GDP would be improving diagnostics
with economic development. This may well be important, but it is
worth noting that we found no relationship between diagnostic
quality and GDP in these studies. Lower quality techniques did
appear to reduce odds of diagnosis (although curiously the highest
odds were seen when diagnostic technique was not recorded), but
inclusion of diagnostic score in our model did not significantly alter
the core findings. Effects of GDP were also similar when analysis
was restricted to studies with high quality diagnosis, and in African
clinical studies which predominantly diagnosed PCP with certainty
(Table 5). Nevertheless, it remains possible that increasing
awareness of PCP among clinicians results in more investigation
or clinical diagnosis: this may explain some of the apparent
increase over time or differences between geographical areas.
However, it seems unlikely that this phenomenon would abolish
the relationship we have demonstrated with GDP, since it would
imply gross under-diagnosis of PCP in LMIC. In Western Europe
before ART was introduced, PCP was responsible for two thirds of
ADI, and 75% of HIV-infected patients developed PCP during
their lifetime [43]: if PCP existed at a similar prevalence in LMIC
it would certainly be identified. In contrast, high quality autopsy
and clinical studies have failed to identify high rates of PCP in low
income settings [2,3,26]. Notably, our model predicts approxi-
mately 6.5-fold increased odds of PCP diagnosis at the GDP levels
of Western European countries in the early 1980s versus low-
income countries (GDP,$1000 per capita), consistent with observed
data.
In terms of other predictors, we observed higher odds for PCP
in Central/South America compared to other areas (we are
Table 5. Results of analysis of predictors of PCP via logistic regression for 18 African adult clinical respiratory studies.
Predictor Exp(B) 95% CI p-value
Median year (per year) N/A
Median year (quadratic) …1 ,0.001
GDP (per $1000) 1.20 1.03–1.40 0.021
Study setting Rural/primary care 0.28 0.08–0.96 0.042
Hospital (secondary level) 1
Hospital (tertiary or University) 0.73 0.45–1.19 0.203
1Odds defined by Exp(0.021+0.021+260.0216[Median year of specific study – Mean of all study median years]).
CI = confidence interval; GDP =per capita Gross Domestic Product (constant US$). N/A =Not Applicable.
doi:10.1371/journal.pone.0069969.t005
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cautious about Middle Eastern results due to low numbers); higher
odds in children than adults; higher odds in nationwide studies
than hospitals and probably the lowest in rural areas; and an
increase over time. All these factors were weaker predictors than
GDP. They may reflect economic differences not reflected in
Figure 5. Sensitivity and specificity for Pneumocystis jirovecii
pneumonia (PCP) of most commonly described signs, symp-
toms, clinical tests or aspects of history. A. predictive of PCP in
adults, B. predictive of absence of PCP in adults, C. predictive of PCP in
children, D. predictive of absence of PCP in children. * Chest x-ray
descriptions most commonly associated with PCP in adults: ‘interstitial
shadowing’; ‘fine shadowing’; ‘minimally abnormal not TB’; ‘diffuse
shadowing’. Chest x-ray descriptions most commonly associated with
PCP in children: ‘alveolar consolidation’; ‘interstitial infiltration’; ‘diffuse
bilateral alveolar shadowing’; ‘consolidation’. ** Chest x-ray descriptions
least commonly associated with PCP in adults: ‘cavities’; ‘hilar lymph
nodes’; ‘classical TB’. TP = True Positive; FP = False Positive; FN= False
Negative; TN= True Negative.
doi:10.1371/journal.pone.0069969.g005
Table 6. Co-infection in PCP patients.
Pathogen Number
Bacteria
Bacterial pathogens unspec 30
Bacterial pneumonia unspec 42
Bacterial sepsis/bacteremia unspec 12
Streptococcus pneumoniae 6
Staphylococcus aureus 10
Klebsiella spp 6
Salmonella spp 1
Proteus spp 1
Pseudomonas spp 2
Haemophilus influenzae 2
Corynebacterium spp 1
Fusarium spp 1
Nocardia spp 2
Mycobacteria
Mycobacterium tuberculosis 103
Myobacteria other than tuberculosis (MOTT) 3
Mycobacteria unspec 6
Fungi
Cryptococcus spp 63
Aspergillus spp 4
Invasive candidiasis 7
Protozoa
Cryptosporidium spp 1
Toxoplasma gondii 1
Viruses
Respiratory virus unspec 26
Cytomegalovirus 104
Respiratory syncitial virus 1
Herpes simplex 2
Adenovirus 2
Other
Infection unspec 5
Total documented co-infections 444
Total PCP patients (from these studies) 1425
Unspec = unspecified.
doi:10.1371/journal.pone.0069969.t006
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Table 7. Case fatality amongst people with a diagnosis of PCP in included studies.
Study Population Years studied
Case fatality (n dead/n with PCP
(%))
African studies
Chakaya et al [32] Adult 1999–2000 5/19 (26.3%)
Malin et al [29] Adult 1992–1993 2/21 (9.52%)
Atzori et al [88] Adult 1991 1/3 (33.3%)
Machiels & Urban [17] Adult 1990 1/4 (25.0%)
Corbett et al [89] Adult 1998–1999 1/8 (12.5%)
van Oosterhout et al [80] Adult 2002–2004 3/6 (50.0%)
Carme et al [90] Adult NR 3/5 (60.0%)
Kibiki et al [83] Adult NR 0/9 (0.0%)
Delport & Brisley [91] Paediatric 1994–1995 2/2 (100%)
Bakeera-Kitaka et al [92] Paediatric 2001 8/20 (40.0%)
Madhi et al [21] Paediatric 2000–2001 20/100 (20.0%)
Ruffini & Madhi [34] Paediatric 1999 16/58 (27.6%)
Zar et al [39] Paediatric 1998 8/19 (42.1%)
Graham et al [36] Paediatric 1996 10/16 (62.5%)
Kamiya et al [93] Paediatric 1995 4/5 (80.0%)
Uriyo et al [94] Paediatric 2003 2/2 (100%)
Rabie et al [95] Paediatric 2003 11/18 (61.1%)
Morrow et al [85] Paediatric 2006–2008 17/43 (39.5%)
South-East/East Asian low and middle income country studies
Tansuphasawadikul et al [31] Adult 2002–2003 1/15 (6.67%)
Narata et al [96] Adult 1986–2004 0/2 (0.0%)
Louie et al [61] Adult 2000 1/5 (20.0%)
Swasdisevi [69] Adult 1994 7/13 (53.8%)
Manaloto et al [42] Adult 1985–1992 5/7 (71.4%)
Ismail et al [97] Combined 1986–1994 3/24 (12.5%)
Chokephaibulkit et al [33] Paediatric 1996–1997 4/9 (44.4%)
South-East/East Asian high income country studies
Lee et al [98] Adult 1985–1996 0/12 (0.0%)
Kim et al [58] Adult 1985–2000 9/37 (24.3%)
Tan et al [68] Adult 1986–1994 1/11 (9.09%)
Middle East studies
Siegman-Igra et al [44] Adult 1982–1987 18/21 (85.7%)
Moses et al [87] Combined 1985–1994 1/14 (7.14%)
Central/South American studies
Weinberg & Duarte [99] Adult 1988–1999 4/15 (26.7%)
Lambertucci et al [100] Adult 1989–1997 2/6 (33.3%)
Santos et al [67] Adult 1986–1991 8/37 (21.6%)
Fallo et al [101] Paediatric 1990–1997 11/79 (13.9%)
Indian studies
Arora & Kumar [102] Adult 1991–1997 3/12 (25.0%)
Udwadia et al [53] Adult 2000–2003 6/38 (15.8%)
Sharma et al [54] Adult 2000–2003 4/10 (40.0%)
Rupali et al [19] Adult 1997–1998 1/7 (14.3%)
Kumarasamy et al [60] Adult 1996–2001 21/36 (58.3%)
George et al [65] Adult 1993–1995 1/1 (100.0%)
Usha et al [103] Adult NR 1/9 (11.1%)
Giri et al [84] Combined 1986–1993 7/9 (77.8%)
Merchant et al [104] Paediatric 1994–2000 2/11 (18.2%)
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national GDP figures (eg greater relative poverty in rural areas,
falling ‘absolute poverty’ over time, or an effect of urbanisation).
Alternatively, there may be biological explanations, most plausible
for the increased risk in children. Finally, they may reflect
disparities in awareness among clinicians of a condition which is
difficult to diagnose.
We evaluated the challenge of clinical diagnosis by assessing
features which might be suggestive of PCP in resource-poor
settings. We discovered several features whose absence (cough,
dyspnoea, fever) or presence (haemoptysis) pointed strongly
against a diagnosis of PCP, but there was little specific to PCP
itself. Although ‘typical’ chest radiographic appearances varied,
the chest x-ray did provide some discriminatory power in adults.
In children, all predictive features performed more poorly.
Some of this diagnostic difficulty may arise from frequent co-
infection. As discussed, in situations of multiple pathogen exposure
we would expect virulent organisms (highly infectious and
pathogenic even in immunocompetent people) to dominate. This
is borne out by high rates of M.tuberculosis and virulent bacterial
infection. Correspondingly, true ‘opportunistic’ infection was not
as highly represented in this data, and was often seen in high
income countries, including two of three defined non-tuberculous
mycobacteria (Israel [44]) and both protozoal infections (Israel
[44] and Bahrain [45]). Cryptococcus was identified in 63 cases, but
the majority were pulmonary infection, which does not necessarily
indicate significant immunosuppression (50 cases are from a single
cardio-respiratory necropsy study [46]). Although CMV was
frequently detected, its significance in respiratory samples from
HIV-infected patients remains uncertain [47,48].
Virulent co-infection might be one explanation for the high case
fatality from PCP in LMIC (although we do not have statistical
proof for this hypothesis). Overall case fatality was 30.8% across
41 studies. This appears to be higher than in high income settings:
one recent US paper reported a case fatality of 8.4% amongst 524
patients [49]. Similarly, we observed a significant negative
relationship between case fatality and GDP in our data.
Table 8. Summary of studies detailing effects of prophylaxis on prevalence of PCP.
Study Population
Country/
Setting
Taking
prophylaxis
Not taking
prophylaxis
Odds
Ratio
95%
confidence
interval Quality assessments
PCP
cases Total
PCP
cases Total
Selection
Score
(max 4)
Comparability
score (max 2)
Diagnostic
score (max
6)
Anekthananon
et al,
2004 [37]
HIV-infected adults,
hospitalisations.
Thailand.
University
hospital.
6 61 35 165 0.41 0.16–1.02 2 2 NR
Knauer et al,
2005 [38]
HIV-infected
adults, interstitial
shadows on CXR.
Thailand.
Tertiary
hospital.
3 24 12 35 0.27 0.07–1.11 2 2 1
Le Minor et al,
2008 [28]
HIV-infected
adults, clinical
lung infection
and CXR changes
Cambodia.
Tertiary
hospital.
3 33 81 127 0.06 0.02–0.20 4 2 6
Madhi et al,
2002 [21]
HIV-infected
children, severe
pneumonia
South Africa.
Public
hospital.
26 69 75 172 0.78 0.44–1.39 4 2 6
Zar et al,
2001 [78]
Children with
pneumonia/
severe pneumonia
or HIV-infected
and admitted to
ICU
South Africa.
University
hospital.
1 59 15 93 0.09 0.01–0.70 2 2 6
Chokephaibulkit
et al,
1999 [33]
HIV-infected
children, severe
pneumonia
Thailand.
University
hospital.
2 9 7 17 0.41 0.06–2.58 2 2 6
Ruffini & Madhi,
2002 [34]
Children (,2 yrs),
‘clinical HIV’ and
severe pneumonia
South Africa.
Secondary and
tertiary hospital.
14 40 37 65 0.41 0.18–0.92 4 2 6
PCP= Pneumocystis jirovecii pneumonia; HIV =Human Immunodeficiency Virus; CXR =Chest X-ray; ICU = Intensive Care Unit.
doi:10.1371/journal.pone.0069969.t008
Table 7. Cont.
Study Population Years studied
Case fatality (n dead/n with PCP
(%))
Madhivanan et al [105] Paediatric 1996–2000 1/5 (20.0%)
Combined =both adult and paediatric populations.
doi:10.1371/journal.pone.0069969.t007
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Antimicrobial therapy against PCP seemed to be largely appro-
priate in these studies, but this by itself appears insufficient to
prevent fatality.
This high fatality emphasises the importance of preventing PCP
in these settings. Little evidence was available for ART, but more
robust evidence was found for the effectiveness of prophylaxis.
However, 8% of adults and 24% of children with PCP in these
settings reported a history of prophylaxis receipt; use of
prophylaxis also poorly predicted the absence of PCP in children
(Figure 5). Practitioners should thus consider PCP even with a
history of prophylaxis. Current thresholds for commencing PCP
prophylaxis seem appropriate, as the majority of PCP patients in
LMIC have significant cell-mediated deficiency (Table 9). How-
ever, median CD4 counts in LMIC were higher than in high
income countries, and there was weak evidence that additional risk
factors (intravenous drug use or commercial sex work) might
predispose to PCP at higher CD4 count.
The effectiveness of ART and prophylaxis in preventing PCP
potentially contradicts the negative relationship between GDP and
risk of PCP, since intuitively higher income countries have greater
access to these interventions. However, this is probably explained
by the fact that PCP is often the presenting illness in HIV-infected
individuals.
Limitations
The search only included three databases, but identified a large
number of studies and is therefore probably comprehensive;
however, we may have missed studies with no recorded cases of
PCP. Inclusion of countries further outside tropical latitude might
have strengthened the relationship with GDP, although we note
that PCP is three times commoner as an ADI in Western Europe
than Eastern Europe [50], which is consistent with our data.
Accurate population denominators were not available for the
included studies, thus results indicate effects on the relative rather
than absolute frequency of PCP diagnosis. However, areas differ
widely in HIV prevalence, and the relative frequency of
complications defines the priorities for policy-makers responsible
for a defined population.
Table 9. CD4 count at presentation with Pneumocystis jirovecii pneumonia in HIV-infected people.
Low and middle income countries
Study Country Adult/Paediatric
Mean
(6103/ml or %)
Median
(6103/ml or %) Range
Kay-Thwe-Han et al [79] Myanmar Adult 132.3 – 0–562
Wood et al [40]1 Malaysia Adult 576 (IVDU patients); 65
(other patients)
– –
von Oosterhout et al [80,81] Malawi Adult 42.5 – 1–103
Manaloto et al [42] Philippines Adult 364 – –
Aderaye et al [82] Ethiopia Adult 59 37 –
Yoong & Cheong [41]1 Malaysia Adult – 719 [calculated] 310–1681
Swasdisevi [69] Thailand Adult – 15 [calculated] 10, 20 [only
recorded twice]
Malin et al [29] Zimbabwe Adult – 134 5–355
Udwadia et al [53] India Adult – 96 –
Sharma et al [54] India Adult – 38 –
Kumarasamy et al [60] India Adult – 87 –
Nissapatorn et al [66] Malaysia Adult – 16.5 –
Lian et al [22] Malaysia Adult – 37 –
Kibiki et al [83] Tanzania Adult – 26 –
Giri et al [84] India Adult+Paediatric – 6 –
Kouakoussui et al [23] Ivory Coast Paediatric – – 5–15%
Ruffini & Madhi [34] South Africa Paediatric 22.5% – –
Morrow et al [85] South Africa Paediatric 13.8% – –
Zar et al [35,39] South Africa Paediatric 16.4% 871 –
High income countries
Study Country Adult/Paediatric Mean Median Range
Kim et al [58] Korea Adult 63 – –
Bellamy et al [55] Singapore Adult – 16.5 –
Fang et al [62]2 Taiwan Adult – 17.5 2–193
Hung et al [86]2 Taiwan Adult – 32 1–193
Oh et al [63] Korea Adult – 16 –
Moses et al [87] Israel Adult+Paediatric – 150 10–582
1Likely overlap between these studies.
2Likely overlap between these studies. VDU= Intravenous drug user.
doi:10.1371/journal.pone.0069969.t009
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Conclusions
These data should alert medical practitioners and policy-
makers. PCP is likely to increase in relative frequency as an HIV
complication in LMIC as they develop economically, and
physicians should familiarise themselves with the presentations of
this infection. Prophylaxis against PCP appears effective and
should be provided according to guidelines. Case fatality from
PCP is high in LMIC settings, and demands improvement.
Increasing odds of PCP with rising GDP implies that wealthier
economic environments allow the CD4 count to fall further than
in LMIC before HIV infection presents. This emphasises the
importance in all settings of identifying HIV infection early. Those
presenting with PCP usually have a CD4 count ,2006103/ml,
and low nadir CD4 predicts poorer long term prognosis from HIV
infection [51].
In summary, we have demonstrated a link between GDP and
diagnosis of PCP, and thereby provide an explanation for the
previously-described epidemiology in tropical and low income
settings.
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